WINTON GROUP Ltd Trims Stake in DexCom, Inc. $DXCM

WINTON GROUP Ltd lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 61.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 27,101 shares of the medical device company’s stock after selling 42,855 shares during the period. WINTON GROUP Ltd’s holdings in DexCom were worth $1,824,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom during the second quarter valued at $26,000. SJS Investment Consulting Inc. raised its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new position in DexCom in the 3rd quarter valued at about $29,000. Sound Income Strategies LLC boosted its stake in shares of DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the last quarter. Finally, Rothschild Investment LLC boosted its stake in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after purchasing an additional 245 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DXCM shares. Robert W. Baird set a $87.00 price objective on shares of DexCom in a research report on Friday, February 13th. Mizuho raised their target price on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Barclays reaffirmed an “underweight” rating and issued a $72.00 target price (up from $71.00) on shares of DexCom in a research note on Friday, February 13th. Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.18.

DexCom Stock Down 1.4%

Shares of DXCM opened at $67.79 on Wednesday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company’s fifty day moving average is $70.73 and its two-hundred day moving average is $68.57. The firm has a market cap of $26.09 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 1.34 and a beta of 1.48. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm posted $0.45 EPS. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.